TRT vs Peptides for Low Testosterone: Which One Is Right for You?

The first question most men ask is which one is better. That's the wrong question, because TRT and peptides are not competing options for the same problem. They are solutions to two completely different problems that happen to share the same symptom.

Low testosterone is the symptom. The cause is what determines the path.

The System You're Working With

Your brain, your pituitary gland, and your testicles operate as a chain, and that chain has a name: the HPG axis, which stands for hypothalamic-pituitary-gonadal axis. Understanding that chain is the whole game here.

At the top sits your hypothalamus, which releases something called GnRH, a signaling molecule that tells the pituitary to act. The pituitary responds by releasing something called LH, which stands for luteinizing hormone, and LH is the direct signal that tells your testicles to produce testosterone. Once testosterone rises high enough, it feeds back to the brain and pituitary and tells them to quiet down. Then testosterone drops, the brake releases, and the cycle starts again.

That system can break at two different points, and the break location changes everything about how you treat it.

If the testicles are the problem, meaning LH is high because the brain is shouting and the testicles still aren't responding, that's called primary hypogonadism, which means the end organ has failed. No amount of upstream signaling fixes a broken receiver. If you give a man with primary hypogonadism a peptide that stimulates his hypothalamus, you are adding more signal to a system that is already maxed out and getting nothing back. TRT is the only rational path in that case.

If the brain and pituitary are the problem, meaning LH is low and testosterone is low together, that's called secondary hypogonadism, which means the signal itself is missing. The testicles are capable of responding. They just aren't being asked. And that is where the peptide and stimulant options become meaningful.

This is why getting your LH tested alongside your testosterone is not a formality. It's the fork in the road. Without that number, you're guessing.

How Each Compound Enters the Chain

Once you've confirmed secondary hypogonadism, you have four compounds worth understanding: kisspeptin, gonadorelin, enclomiphene, and HCG. They each enter the HPG axis at a different level, which is why they have different effects and different limitations.

Kisspeptin is a neuropeptide that acts on the hypothalamus to trigger GnRH release, and GnRH is what fires the whole chain downstream. Think of kisspeptin as the switch that turns on the factory. Work published in Clinical Endocrinology by George et al. in 2013 showed that kisspeptin infusion increased LH pulse frequency and raised both LH and testosterone in men with secondary hypogonadism related to type 2 diabetes, which was proof that the upstream pathway could be reactivated in men whose signal had gone quiet.

The pharmacokinetics matter here in a practical way. Research published in PLoS One by d'Anglemont de Tassigny and colleagues in 2017 measured the plasma half-life of different kisspeptin fragments. KP-10, the short version, clears in roughly 4 minutes. KP-54, the longer version, has a half-life of approximately 32 minutes and produces more sustained LH stimulation. That difference in duration is the reason KP-54 is more useful clinically. One injection can drive the pulse generator over a longer window rather than producing a single spike and clearing.

Gonadorelin works at the same level, stimulating the hypothalamus to release GnRH, but it clears the system in 2 to 4 minutes. One injection, one pulse, done. It can be useful in specific contexts but the rapid clearance limits its ability to sustain the rhythm that healthy testosterone production requires.

Enclomiphene enters the system one level lower, at the pituitary. It is what's called a SERM, which stands for selective estrogen receptor modulator, and its job is to block the estrogen receptor at the pituitary so the brain perceives less estrogen feedback and releases more LH as a result. Wiehle et al. published a phase II RCT in BJU International in 2013 testing 6.25, 12.5, and 25 mg daily doses. The 25 mg group reached an average total testosterone of 604 ng/dL at 6 weeks, and LH and FSH both remained elevated, which means the testes were still being stimulated by the body's own signal rather than suppressed. That's the key structural advantage of this approach over TRT.

The limitation is that a systematic review and meta-analysis published in Andrology by Huijben et al. in 2022 covering 19 studies and 1,642 patients confirmed that clomiphene citrate, which is in the same class, raises SHBG alongside testosterone. SHBG is something called sex hormone binding globulin, which is a protein that binds to testosterone in the bloodstream and makes it unavailable to tissues. So total testosterone goes up on paper, but free testosterone, the fraction that actually acts on your cells, doesn't always follow proportionally. Running enclomiphene on its own means you're potentially raising a number without fully capturing the benefit.

HCG, which stands for human chorionic gonadotropin, skips the hypothalamus and pituitary entirely and acts directly at the testicles, mimicking LH. It's the most direct lever in this category. A dose-response study published in JCEM by Coviello et al. in 2005 quantified exactly how much testicular testosterone production different HCG doses could maintain. At 125 IU every other day, men maintained about 25% of their baseline intratesticular testosterone. At 250 IU, that number jumped to 93%. At 500 IU, they were at 126% of baseline. That dose-response relationship is why the 500 to 1000 IU every other day range is commonly used clinically when the goal is meaningful testosterone support.

A small study published in Cureus by Rainer et al. in 2022 followed 28 men who transitioned from TRT to HCG monotherapy and found their testosterone increased from 307 to 422 ng/dL, while hematocrit, which is a marker that TRT tends to push upward and that carries cardiovascular implications, significantly decreased. A separate study published in Cureus by Zucker et al. in 2022 tracking 31 men on weekly HCG monotherapy found 86% improvement in erectile dysfunction and 80% improvement in libido, with no changes to hematocrit, PSA, or HbA1c.

The Combination Logic and What the Data Actually Say

None of the three compounds above is a complete solution on its own. Kisspeptin works upstream but clears quickly. Enclomiphene raises LH but also raises SHBG. HCG stimulates the testicles directly but bypasses everything above it, so it does nothing to maintain the brain's own signaling. Using all three together addresses each gap in the others, with one compound working at each level of the axis.

It's worth being direct about what the evidence base for this specific combination looks like: no published clinical trial has tested kisspeptin plus enclomiphene plus HCG together. The rationale is pharmacologically sound because each compound operates through a distinct mechanism, but the combination itself is supported by the logic of complementary mechanisms rather than a randomized controlled trial. That's an important distinction when you're evaluating whether to pursue this approach.

What the larger dataset does support is that fertility-preserving approaches as a category can achieve outcomes comparable to TRT in men with secondary hypogonadism. Clift et al. published a cohort study in World Journal of Men's Health covering 6,999 men comparing combinations of HCG plus TRT, clomiphene citrate plus TRT, and clomiphene citrate alone against each other. All groups achieved total testosterone levels in the 680 to 764 ng/dL range, and quality of life scores measured by the QADAM scale improved significantly across all groups, from 7.86 to 9.50, with p values below 0.001. The distinction that matters is that clomiphene monotherapy preserved LH and FSH, meaning those men maintained their own axis function, while the groups that included TRT suppressed it.

Dadhich et al. published a study in the Indian Journal of Urology in 2017 comparing testosterone supplementation directly to clomiphene in 127 men, and the symptom data is worth noting. TRT improved 7 out of 10 symptom subscores on the qADAM scale. Clomiphene improved only 1, the sports performance subscale, and actually worsened libido, dropping the libido score from 3.75 to 3.2 with a p value of 0.04, despite raising total testosterone. This is exactly what you would predict if SHBG were binding the new testosterone before it could reach tissue. Total testosterone up, free testosterone effectively constrained, symptoms not improved.

The Decision and the Protocol

The decision tree is simpler than the biochemistry makes it sound.

Get your LH and total testosterone tested at the same time. If LH is high and testosterone is low, TRT. If LH is low and testosterone is low, you have options.

The combination protocol that aligns with the pharmacological rationale runs kisspeptin at 100 to 200 micrograms subcutaneously every other day, because research from Jayasena et al. published in JCEM in 2009 showed that twice-daily dosing causes receptor desensitization within weeks while twice-weekly dosing maintained response over 8 weeks, so spacing the doses is not optional. Enclomiphene at 12.5 to 25 milligrams daily. HCG at 500 to 1000 IU every other day based on the Coviello dose-response data showing 500 IU maintains intratesticular testosterone above baseline.

Run the combination for 8 to 12 weeks, then recheck LH and total testosterone to assess whether the axis is holding.

If you're primarily concerned with preserving fertility and testicular function, the evidence for HCG and SERMs individually is the most established. If you want the axis to continue generating its own signal rather than being dependent on an external source, that concern pushes you away from TRT as a first-line choice even when the numbers would justify it.

Most of the conversation about TRT versus peptides frames this as a question of which is more effective. But the more useful frame is: which part of the system is broken? A man with primary hypogonadism and a man with secondary hypogonadism both have low testosterone. They have almost nothing else in common medically. One of them needs a replacement. The other needs a signal. Giving a replacement to someone who needs a signal, or a signal to someone whose receiver is broken, is not a bad choice. It is the wrong intervention entirely.

That's the whole point of the LH number.

---

References

1. Jayasena CN et al. 2009. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. JCEM. Finding: Twice-daily kisspeptin dosing caused receptor desensitization tachyphylaxis; twice-weekly dosing maintained response over 8 weeks. Source
2. Huijben M et al. 2022. Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis. Andrology. Finding: 19 studies, 1,642 patients. CC increased total testosterone by 2.60 units 95% CI 1.82-3.38. Also increased SHBG. Source
3. Dadhich P et al. (2017). Testosterone supplementation therapy vs clomiphene citrate. Indian Journal of Urology. Finding: n=127. TST improved 7/10 qADAM symptom subscores. CC improved only 1 (sports performance) and worsened libido (3.75 to 3.2, p=0.04) despite increasing total T. PMID 28717276.
4. Kaminetsky J et al. 2013. Oral enclomiphene citrate stimulates endogenous production of testosterone and sperm counts in men with low testosterone. Journal of Sexual Medicine. Finding: Phase IIB RCT, n=12. Enclomiphene increased TT to 525 ng/dL, maintained elevated LH/FSH, and elevated sperm counts. Source
5. Clift AK et al. 2026. Pituitary Axis Impacts and Effectiveness of Clomiphene and Human Chorionic Gonadotropin in Treating Hypogonadism: Cohort Study. World Journal of Men's Health. Finding: n=6,999. hCG+TRT, CC+TRT, and CC monotherapy all achieved comparable testosterone levels 23.58-26.52 nmol/L, ~680-764 ng/dL and quality of life improvements QADAM scores 7.86 to 9.50, all p<0.001. CC monotherapy preserved LH/FSH. Source
6. Rainer Q et al. 2022. The Safety of Human Chorionic Gonadotropin Monotherapy Among Men With Previous Exogenous Testosterone Use. Cureus. Finding: n=28, men transitioning from TRT to HCG monotherapy. T increased from 307 to 422 ng/dL in men whose baseline was outside their TRT window. Significant decrease in hematocrit. No thromboembolic events. Source
7. Zucker I et al. 2022. Efficacy and Safety of Human Chorionic Gonadotropin Monotherapy for Men With Hypogonadal Symptoms and Normal Testosterone. Cureus. Finding: n=31, weekly HCG monotherapy. 86% improvement in erectile dysfunction, 80% improvement in libido. No changes to hematocrit, PSA, or HbA1c. Source
8. Crosnoe LE et al. 2013. Exogenous testosterone: a preventable cause of male infertility. Translational Andrology and Urology. Finding: Review. HCG therapy protects testicular function during TRT. SERMs clomiphene are safe and effective for maintaining testosterone and fertility. Low-dose HCG with exogenous testosterone is an alternative strategy. Source
9. George JT et al. 2013. Kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clinical Endocrinology. Finding: Kisspeptin-10 infusion increased LH pulse frequency and LH/T in hypotestosteronemic men with T2DM secondary hypogonadism. Proof of concept for kisspeptin in central hypogonadism. Source
10. Wiehle RD et al. 2013. Enclomiphene citrate stimulates testosterone while reducing signs and symptoms of hypogonadism. BJU International. Finding: Phase II RCT testing 6.25, 12.5, and 25 mg enclomiphene daily. 25 mg group: TT rose to 604 ng/dL at 6 weeks. All doses significantly raised TT into normal range with maintained LH/FSH. Source
11. Coviello AD et al. 2005. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. JCEM. Finding: Dose-response study. 125 IU HCG EOD maintained 25% of baseline ITT. 250 IU maintained 93%. 500 IU maintained 126%. Validates HCG dose-response for testicular function. Source
12. d'Anglemont de Tassigny X et al. 2017. Pharmacokinetic assessment of kisspeptin peptides. PLoS One. Finding: KP-54 plasma half-life ~32 minutes. KP-10 half-life ~4 minutes. KP-54 produces more sustained LH stimulation and can cross the blood-brain barrier. Source
13. No published clinical trial has tested the specific combination of kisspeptin + enclomiphene + HCG. Individual compound data supports the pharmacological rationale (each enters the HPG axis at a different level). Josh's kisspeptin video (14K views) outlines the combination approach based on complementary mechanisms of action.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness